Etid klinik pou BPCO nan Georgia
12 etid pou BPCO ap chèche patisipan nan sit nan Georgia.
Vil nan Georgia
Tèks ofisyèl etid la (Anglè)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
Ap rekriteFaz 2
Laj 40 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07684820A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
Ap rekriteFaz 4
Laj 40 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06883305A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- ak 1 plis
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06878261A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
Ap rekriteFaz 2/3
Laj 35 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Aug 26, 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
Ap rekriteFaz 3
Laj 40 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
Ap rekriteFaz 2
Laj 35 a 89 · Tout sèks · Mizajou May 15, 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- ak 1 plis
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Apr 9, 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2025 · NCT06122077Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.